Diabetes
| T2D
Diabetes
T2D

Effect of orforglipron versus placebo and dulaglutide on glycaemic control and body weight in patients with type 2 diabetes

book_2 Source: EASD 2023 - Oral Presentation
calendar_today Published on Medfyle: October 2023
import_contacts 7 min
headphones 6 min

In this medfyle

The study examined the efficacy of orforglipron in reducing HbA1c, fasting serum glucose, and bodyweight. Orforglipron led to clinically significant reductions in HbA1c, fasting serum glucose, and body weight with an adverse events profile consistent with other GLP-1 RAs.

Expert commentary

Vivian Fonseca, MD

Professor of Medicine and Pharmacology 
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes 
Chief, Section of Endocrinology
Tulane University Health Sciences Center 
New Orleans, LA, USA

About this Medfyle
Read more arrow_downward Hide arrow_upward

This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).

The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.

©2023 Infomedica-Medfyle. All rights reserved.


Feedback